Ablynx NV, the Belgian pharmaceutical company that derives therapeutic proteins from antibodies, said its revenues rose 150% in 2007 to €9.9 million from €3.9 million a year earlier. But the company’s loss narrowed only slightly to €12.5 million from €13.2 million.
